How many stocks are there of Cyclopharm?
The current number of stocks of Cyclopharm is 92.66 M undefined.
Cyclopharm Stocks 2025
Cyclopharm Stocks
92.66 M
Ticker
CYC.AX
ISIN
AU000000CYC5
In 2025, Cyclopharm had 92.66 M outstanding stocks, a 0% change from the 92.66 M stocks in the previous year.
The Cyclopharm Stocks history
| YEAR | NUMBER OF STOCKS (undefined AUD) |
|---|---|
| 2027e | 92.66 |
| 2026e | 92.66 |
| 2025e | 92.66 |
| 2024e | 92.66 |
| 2023 | 92.66 |
| 2022 | 92.18 |
| 2021 | 89.69 |
| 2020 | 76.59 |
| 2019 | 68.12 |
| 2018 | 67.97 |
| 2017 | 67.89 |
| 2016 | 59.64 |
| 2015 | 57.9 |
| 2014 | 58.36 |
| 2013 | 58.14 |
| 2012 | 122.43 |
| 2011 | 35.21 |
| 2010 | 36.78 |
| 2009 | 36.78 |
| 2008 | 30.51 |
| 2007 | 29.28 |
| 2006 | 28.65 |
| 2005 | 28.15 |
Cyclopharm shares outstanding AU000000CYC5 ·
The number of shares was Cyclopharm in 2024 — This indicates how many shares 92.664 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
3 years
5 years
10 years
25 Years
Max
Number of stocks
Details
Revenue, EBIT and Earnings per share
ⓘRevenue Per Share
Revenue per share represents the total revenue Cyclopharm earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT Per Share
EBIT per share indicates Cyclopharm's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income Per Share
Income per share, or earnings per share (EPS), reveals the portion of Cyclopharm’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected Values
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Cyclopharm's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
| Number of stocks | |
|---|---|
| 2005 | 28.15 M Aktien |
| 2006 | 28.65 M Aktien |
| 2007 | 29.28 M Aktien |
| 2008 | 30.51 M Aktien |
| 2009 | 36.78 M Aktien |
| 2010 | 36.78 M Aktien |
| 2011 | 35.21 M Aktien |
| 2012 | 122.43 M Aktien |
| 2013 | 58.14 M Aktien |
| 2014 | 58.36 M Aktien |
| 2015 | 57.9 M Aktien |
| 2016 | 59.64 M Aktien |
| 2017 | 67.89 M Aktien |
| 2018 | 67.97 M Aktien |
| 2019 | 68.12 M Aktien |
| 2020 | 76.59 M Aktien |
| 2021 | 89.69 M Aktien |
| 2022 | 92.18 M Aktien |
| 2023 | 92.66 M Aktien |
| 2024e | 92.66 M Aktien |
| 2025e | 92.66 M Aktien |
| 2026e | 92.66 M Aktien |
| 2027e | 92.66 M Aktien |
Cyclopharm Aktienanalyse
What does Cyclopharm do?
Cyclopharm Ltd is an Australian company that was founded in 1986 and has since been developing innovative medical solutions. The company operates in the field of nuclear medicine and focuses on providing diagnostic and therapeutic products and services. The history of Cyclopharm Ltd began with the development of the Technetium-99m generator, an instrument for generating radioisotopes that can be used in medical imaging. Since then, the company has expanded its offerings and now offers a wide range of products and services. Cyclopharm Ltd's business model is based on research and development of new solutions based on the needs of the medical community and patients. The company works closely with doctors, scientists, and other experts to ensure that its products and services meet the highest standards. Cyclopharm Ltd is divided into various divisions to coordinate and optimize its activities. These include diagnostics, therapy, research and development, as well as sales and marketing. Each division works closely with the others to ensure that the company achieves its goals and provides optimal customer care. Some of Cyclopharm Ltd's most well-known products include the Technetium-99m generator and the radiopharmaceutical Technegas. Technegas is a gas used for lung imaging and plays an important role in diagnosing lung problems. The radiopharmaceutical is produced using the Technetium-99m generator and is an important addition to medical imaging. In addition, Cyclopharm Ltd also develops therapeutic solutions that can be used to treat cancer and other diseases. These include radiopharmaceuticals used in radiation therapy, as well as other solutions tailored to the individual needs of patients. Cyclopharm Ltd is also actively working on improving and expanding its products and services. The company invests in research and development to develop innovative solutions that can improve medical imaging and therapy. Additionally, the company works closely with its customers to better understand their needs and offer them tailored solutions. Overall, Cyclopharm Ltd is an innovative and goal-oriented company that focuses on providing diagnostic and therapeutic solutions in the field of nuclear medicine. The company has a long history of leadership in this field and will continue to be at the forefront of developing solutions that improve the lives of patients and medical professionals. Cyclopharm ist eines der beliebtesten Unternehmen auf Eulerpool.com.Stocks Details
Evaluating Cyclopharm's Shares Outstanding
Cyclopharm's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.
Year-to-Year Comparison
Tracking the changes in Cyclopharm’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.
Impact on Investments
For investors, understanding Cyclopharm’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.
Interpreting Changes in Shares Outstanding
Variances in Cyclopharm’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.
Frequently Asked Questions about Cyclopharm stock
What does Number of Shares / OutstandingShares mean?
The outstanding shares (or issued shares) of Cyclopharm are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.
How has the number of shares of Cyclopharm evolved in recent years?
The number of shares of Cyclopharm has increased by 0% gestiegen compared to last year.
What does the number of shares mean for investors?
The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.
Why does the number of stocks fluctuate?
There are various factors that can lead to a change. Cyclopharm as a company can issue new shares, carry out stock splits or reverse splits.
Does the number of shares have an impact on the performance of Cyclopharm?
There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).
How much dividend does Cyclopharm pay?
Over the past 12 months, Cyclopharm paid a dividend of 0.01 AUD . This corresponds to a dividend yield of about 0.44 %. For the coming 12 months, Cyclopharm is expected to pay a dividend of 0.01 AUD.
What is the dividend yield of Cyclopharm?
The current dividend yield of Cyclopharm is 0.44 %.
When does Cyclopharm pay dividends?
Cyclopharm pays a quarterly dividend. This is distributed in the months of May, October, April, October.
How secure is the dividend of Cyclopharm?
Cyclopharm paid dividends every year for the past 0 years.
What is the dividend of Cyclopharm?
For the upcoming 12 months, dividends amounting to 0.01 AUD are expected. This corresponds to a dividend yield of 0.41 %.
In which sector is Cyclopharm located?
Cyclopharm is assigned to the 'Health' sector.
Wann musste ich die Aktien von Cyclopharm kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Cyclopharm from 9/11/2023 amounting to 0.005 AUD, you needed to have the stock in your portfolio before the ex-date on 9/1/2023.
When did Cyclopharm pay the last dividend?
The last dividend was paid out on 9/11/2023.
What was the dividend of Cyclopharm in the year 2024?
In the year 2024, Cyclopharm distributed 0.01 AUD as dividends.
In which currency does Cyclopharm pay out the dividend?
The dividends of Cyclopharm are distributed in AUD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Cyclopharm
Our stock analysis for Cyclopharm Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cyclopharm Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
